NCT05133830View on ClinicalTrials.gov

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

52

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions

Pruritus

Interventions

DRUG

Obeticholic acid

OCA will be administered

DRUG

Linerixibat

Linerixibat will be administered

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY